Veracyte has completed a $600 million cash deal to acquire Decipher Biosciences, expanding its position in the genomics-driven cancer diagnostics sector. Decipher Biosciences is now a subsidiary of Veracyte.
Tina Nova, PhD, who is the previous president and chief executive officer at Decipher, has been appointed general manager of urologic cancers at Veracyte. She will continue to oversee the company's San Diego operations, including a CLIA-certified and College of American Pathologists (CAP)-accredited laboratory.